Brief: Intensity Therapeutics Announces Patients Receiving INT230-6 Prior To Start Of Standard-Of-Care May Achieve High Levels Of Tumor Necrosis In Ongoing Randomized Controlled Phase 2 Invincible-4 Study
11/06/2025 14:19
June 11 (Reuters) - Intensity Therapeutics Inc INTS.O: INTENSITY THERAPEUTICS, INC. ANNOUNCES PATIENTS RECEIVING INT230-6 PRIOR TO THE START OF STANDARD-OF-CARE MAY ACHIEVE HIGH LEVELS OF TUMOR NECROSIS IN THE ONGOING RANDOMIZED CONTROLLED PHASE 2 INVINCIBLE-4 STUDY Source text: ID:nPn2yD2wJa Further company coverage: INTS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Intensity Therapeutics
See all newsIntensity Therapeutics Q2 net loss widens as R&D costs rise
Brief: Intensity Therapeutics Q2 Operating Income USD -3.084 Million
Intensity Therapeutics Q1 net loss narrows on lower R&D costs
Brief: Intensity Therapeutics Q1 Operating Income USD -2.526 Million
Brief: Intensity Therapeutics Inc - Increases ATM Offering Capacity To $60 Million On March 23, 2026 - SEC Filing